Table 4 Mortality in the COVID group, univariate analysis
From: Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome
Survivors (n = 41) | Non-survivors (n = 9) | p | |
|---|---|---|---|
Clinical data | |||
Age (years) | 60.1 ± 2.3 | 78.9 ± 5.1 | 0.002 |
Height (cm) | 174 ± 2 | 169 ± 6 | 0.18 |
Weight (kg) | 88.1 ± 3.5 | 77.3 ± 7.8 | 0.20 |
BMI (kg/m2) | 28.9 ± 1.0 | 27.3 ± 2.2 | 0.49 |
Sex ratio (M/F) | 29/12 | 7/2 | 0.73 |
Hypertension (%) | 42 | 89 | 0.01 |
Diabetes (%) | 20 | 33 | 0.42 |
Smoker (%) | 0.76 | ||
Never | 89 | 79 | |
Former | 11 | 19 | |
Current | - | 2 | |
COPD (%) | 7 | 44 | 0.003 |
Renal failure (%) | 14 | 56 | 0.006 |
Cancer (%) | 11 | 13 | 0.82 |
CT scan findings | |||
Thymus CT scan core 0 (%) | 24 | 78 | 0.009 |
Lung CT scan score | 3 [2–4] | 4 [2–5] | 0.38 |
Data at admission | |||
PaO2/FIO2 | 290 ± 31 | 264 ± 51 | 0.65 |
Haemoglobin (g/L) | 12.0 ± 0.3 | 10.6 ± 0.7 | 0.06 |
Leukocytes (× 109/L) | 7.6 ± 0.6 | 7.9 ± 1.3 | 0.79 |
Lymphocytes (× 109/L) | 1.3 ± 0.2 | 0.4 ± 0.4 | 0.05 |
Lymphocytes (%) | 18 ± 2 | 8 ± 3 | 0.009 |
Monocytes (× 109/L) | 0.63 ± 0.05 | 0.49 ± 0.11 | 0.27 |
Monocytes (%) | 11 ± 1 | 7 ± 3 | 0.37 |
Fibrinogen (g/L)* | 6.34 ± 0.4 | 7.10 ± 1.0 | 0.46 |
D-dimer (ng/mL)* | 4579 ± 1158 | 4510 ± 2577 | 0.48 |
CRP (mg/L) | 111 ± 15 | 206 ± 32 | 0.01 |